BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36471402)

  • 1. p53 immunostaining pattern is a useful surrogate marker for TP53 gene mutations.
    Sung YN; Kim D; Kim J
    Diagn Pathol; 2022 Dec; 17(1):92. PubMed ID: 36471402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
    Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
    Am J Surg Pathol; 2023 Oct; 47(10):1144-1150. PubMed ID: 37528644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
    Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
    Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.
    Kortekaas KE; Solleveld-Westerink N; Tessier-Cloutier B; Rutten TA; Poelgeest MIE; Gilks CB; Hoang LN; Bosse T
    Histopathology; 2020 Jul; 77(1):92-99. PubMed ID: 32236967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
    Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
    Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
    Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
    [No Abstract]   [Full Text] [Related]  

  • 8. Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma.
    Li X; Luo D; Zhang L; Li Q; Fan J; Zhang J; Huang B; Yang M; Nie X; Chang X; Pan H
    BMC Cancer; 2023 Oct; 23(1):1008. PubMed ID: 37858047
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Na K; Sung JY; Kim HS
    Anticancer Res; 2017 Dec; 37(12):6697-6703. PubMed ID: 29187446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
    Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
    Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
    Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
    Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical staining patterns of p53 predict the mutational status of TP53 in oral epithelial dysplasia.
    Sawada K; Momose S; Kawano R; Kohda M; Irié T; Mishima K; Kaneko T; Horie N; Okazaki Y; Higashi M; Tamaru JI
    Mod Pathol; 2022 Feb; 35(2):177-185. PubMed ID: 34404905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for
    Li J; Wang J; Su D; Nie X; Liu Y; Teng L; Pang J; Wu H; Liang Z
    Gastroenterol Res Pract; 2021; 2021():2510195. PubMed ID: 34956360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical correlates of TP53 somatic mutations in cancer.
    Murnyák B; Hortobágyi T
    Oncotarget; 2016 Oct; 7(40):64910-64920. PubMed ID: 27626311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance.
    Dundr P; Hájková N; Kendall Bártů M; Cibula D; Drozenová J; Fabian P; Fadare O; Frühauf F; Hausnerová J; Hojný J; Laco J; Lax SF; Matěj R; Méhes G; Michálková R; Němejcová K; Singh N; Stolnicu S; Švajdler M; Zima T; McCluggage WG; Stružinská I
    Pathology; 2023 Oct; 55(6):785-791. PubMed ID: 37500307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
    Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
    Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer.
    Kim KM; Ahn AR; Park HS; Jang KY; Moon WS; Kang MJ; Ha GW; Lee MR; Chung MJ
    BMC Cancer; 2022 Aug; 22(1):940. PubMed ID: 36045334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoplasmic Pattern p53 Immunoexpression in Pelvic and Endometrial Carcinomas With TP53 Mutation Involving Nuclear Localization Domains: An Uncommon But Potential Diagnostic Pitfall With Clinical Implications.
    Rabban JT; Garg K; Ladwig NR; Zaloudek CJ; Devine WP
    Am J Surg Pathol; 2021 Nov; 45(11):1441-1451. PubMed ID: 33899789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.